Study: comparison of glisenings, PCO in hydrophobic acrylic IOLs

Article

Investigators evaluated and compared the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed between 2 hydrophobic acrylic intraocular lenses (IOLs).

A comparison of 2 hydrophobic acrylic intraocular lenses (IOLs) evaluated the long-term formation of posterior capsular opacification (PCO) and the rate of glistenings that developed. The investigators found that the Hoya Vivinex had significantly lower development of glistenings compared with the Alcon AcrySof lens,1 according to Gerd Auffarth, MD, and colleagues. He is from the University of Heidelberg, Heidelberg, Germany.

The investigators conducted a prospective, multicentric, randomized, paired-eye, open-label study that included 87 subjects who underwent cataract surgery with IOL implantation; of these, 67 patients completing the 3-year follow-up examination.

The completer population consisted of 32 subjects implanted with the Hoya IOL and 35 implanted with the Alcon IOL. The primary endpoints were an evaluation of glistenings and measurement of PCO. The secondary outcomes were measurement of the best-corrected distance visual acuity (VA), contrast acuity, uncorrected VAs, subjective refraction, medical and lens complication rates, adverse events, and optical/visual symptoms.

The patients were followed at 6-months and 1, 2 and 3 years postoperatively. At the 3-year follow-up, the mean PCO scores were 0.121 ± 0.193 for eyes implanted with the Hoya IOL versus 0.239 ± 0.463 for those with the Alcon IOL, a difference that reached significance (p = 0.026). The Hoya IOL had a significantly lower rate of glistening occurrence throughout the 3 years postoperatively (0.14 ± 0.26) compared to the Alcon IOL (1.79 ± 1.43; p < 0.0001).

The postoperative VAs improved from baseline with both IOL (p < 0.0001) and remained stable through the 3-year follow-up period. The eyes that received the Hoya IOL had a significantly lower occurrence of glistening at 3 years compared with the Alcon IOL (p < 0.0001). The incidence rates of PCO were very low and comparable with both IOLs.

Reference
Auffarth GU, Brézin A, Lignereux F, et al. Randomized multicenter trial to assess posterior capsule opacification and glistenings in two hydrophobic acrylic intraocular lenses. Sci Rep. 2023;13:2822; https://doi.org/10.1038/s41598-023-29855-8
Recent Videos
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
© 2025 MJH Life Sciences

All rights reserved.